These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 19860714)
1. The therapeutic potential of cell-internalizing aptamers. Zhou J; Rossi JJ Curr Top Med Chem; 2009; 9(12):1144-57. PubMed ID: 19860714 [TBL] [Abstract][Full Text] [Related]
2. Current progress of RNA aptamer-based therapeutics. Zhou J; Bobbin ML; Burnett JC; Rossi JJ Front Genet; 2012; 3():234. PubMed ID: 23130020 [TBL] [Abstract][Full Text] [Related]
3. [Advance in the study of targeting delivery system for siRNA mediated by aptamers]. Wang XL; Wang QQ; Song HF Yao Xue Xue Bao; 2012 Jul; 47(7):850-5. PubMed ID: 22993847 [TBL] [Abstract][Full Text] [Related]
4. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy. Li X; Zhao Q; Qiu L J Control Release; 2013 Oct; 171(2):152-62. PubMed ID: 23777885 [TBL] [Abstract][Full Text] [Related]
9. Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery. Liao J; Liu B; Liu J; Zhang J; Chen K; Liu H Expert Opin Drug Deliv; 2015 Mar; 12(3):493-506. PubMed ID: 25430795 [TBL] [Abstract][Full Text] [Related]
10. The application of aptamers in cancer research: an up-to-date review. Hu M; Zhang K Future Oncol; 2013 Mar; 9(3):369-76. PubMed ID: 23469972 [TBL] [Abstract][Full Text] [Related]
11. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. Wang CW; Chung WH; Cheng YF; Ying NW; Peck K; Chen YT; Hung SI J Allergy Clin Immunol; 2013 Sep; 132(3):713-722.e11. PubMed ID: 23791505 [TBL] [Abstract][Full Text] [Related]
13. SELEX methods on the road to protein targeting with nucleic acid aptamers. Bayat P; Nosrati R; Alibolandi M; Rafatpanah H; Abnous K; Khedri M; Ramezani M Biochimie; 2018 Nov; 154():132-155. PubMed ID: 30193856 [TBL] [Abstract][Full Text] [Related]
14. Aptamers as targeted therapeutics: current potential and challenges. Zhou J; Rossi J Nat Rev Drug Discov; 2017 Mar; 16(3):181-202. PubMed ID: 27807347 [TBL] [Abstract][Full Text] [Related]
16. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles. Sivakumar P; Kim S; Kang HC; Shim MS Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426 [TBL] [Abstract][Full Text] [Related]
17. Advances in Aptamers-Based Applications in Breast Cancer: Drug Delivery, Therapeutics, and Diagnostics. Gholikhani T; Kumar S; Valizadeh H; Mahdinloo S; Adibkia K; Zakeri-Milani P; Barzegar-Jalali M; Jimenez B Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430951 [TBL] [Abstract][Full Text] [Related]
18. Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents. Kim M; Kim DM; Kim KS; Jung W; Kim DE Molecules; 2018 Apr; 23(4):. PubMed ID: 29617327 [TBL] [Abstract][Full Text] [Related]
19. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. Zhou J; Li H; Zhang J; Piotr S; Rossi J J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942 [TBL] [Abstract][Full Text] [Related]
20. Aptamer applications for targeted cancer therapy. Barbas AS; Mi J; Clary BM; White RR Future Oncol; 2010 Jul; 6(7):1117-26. PubMed ID: 20624124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]